期刊文献+

左旋多巴对帕金森病大鼠结肠神经递质的影响 被引量:4

Effects of Levodopa on colonic neurotransmitters of rats model of Parkinson's disease
下载PDF
导出
摘要 目的探讨左旋多巴对帕金森病(PD)大鼠模型结肠平滑肌收缩性和神经递质的影响。方法 6-羟多巴胺损毁制备偏侧PD大鼠模型。动物分为对照组、PD组、左旋多巴组、PD+左旋多巴组4组;左旋多巴组和PD+左旋多巴组给予左旋多巴灌胃治疗35 d,对照组和PD组给予生理盐水灌胃治疗35 d;采用生物信号采集分析系统记录各组结肠平滑肌收缩频率和幅度;免疫组织化学SP法观察结肠肌间神经丛神经元型一氧化氮合酶(nN O S)、酪氨酸羟化酶(TH)和乙酰胆碱转移酶(C hAT)的变化;R T-PC R检测nN O S、TH、C hAT m R-N A在结肠的表达。结果①与对照组比较,PD组和PD+左旋多巴组收缩频率和幅度明显下降(P<0.05);与PD组比较,PD+左旋多巴组收缩频率和幅度增加(P<0.05)。②与对照组比较,PD组和PD+左旋多巴组nN O S免疫阳性产物积分光密度(IO D)和nN O S m R N A表达明显升高(P<0.05),TH免疫阳性产物IO D和TH m R N A表达明显降低(P<0.05);与PD组比较,PD+左旋多巴组nN O S免疫阳性产物IO D和m R N A表达降低(P<0.05),TH免疫阳性产物IO D和m R N A表达升高(P<0.05);各组C hAT免疫阳性产物IO D和C hAT m R N A表达无明显差异。结论 PD大鼠结肠收缩性下降,其机制可能与nN O S的增多和多巴胺的减少有关。左旋多巴可改善PD大鼠结肠收缩功能,可能与nN O S的减少和多巴胺的增多有关。 【Objective】 To investigate the effects of Levodopa on the contractility of colon smooth muscle and neurotransmitters of colon of rat Parkinson's disease models induced by 6-OHDA.【Methods】 Unilateral 6-hydroxydo-pamine lesioned rat model of PD was established.Rats were divided into control group,untreated PD group,Levodopa group,Levodopa treated PD group.Levodopa group and Levodopa treated PD group were administered with Levodopa once daily for 35 days.Control group and untreated PD group were administered with normal saline solution once daily for 35 days.Observe the contraction frequency and amplitude of colon smooth muscle by biological signal acquisition system.Immunohistochemistry was used to stain myenteric neurons for neuronal nitric oxide synthase(nNOS),tyrosine hydroxylase(TH) and choline acetyl transferase(ChAT) in colon tissues.In addition,RT-PCR technique was used to analyze the expression of nNOS,TH and ChAT in colon tissues.【Results】 Compared with control group,the frequency and amplitude of colon contraction in untreated PD group and Levodopa treated PD group significantly decreased(P 0.05);Compared with untreated PD group,the frequency and amplitude of colon contraction in Levodopa treated PD group obviously increased(P 0.05).Compared with control group,the integrated option density(IOD) of nNOS-immunoresponse(IR) positive products and the levels of nNOS mRNA of colon in untreated PD group and Levodopa treated PD group significantly increased(P 0.05),the IOD of TH-IR positive products and the levels of TH mRNA of colon in untreated PD group and Levodopa treated PD group significantly decreased(P 0.05).Compared with untreated PD group,the IOD of nNOS-IR positive products and the levels of nNOS mRNA of colon in Levodopa treated PD group obviously decreased(P 0.05),the IOD of TH-IR positive products and the levels of TH mRNA of colon in Levodopa treated PD group obviously increased(P 0.05).The IOD of ChAT-IR positive products and the levels of ChAT mRNA of colon in each groups had no significant difference(P 0.05).【Conclusions】 The increase of nNOS and decrease of dopamine may be responsible for the dysfunction of colon in rat PD models,the decrease of nNOS and the increase of dopamine may be responsible for the effects of Levodopa on the dysfunction of colon in rat PD models.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2011年第20期2365-2369,共5页 China Journal of Modern Medicine
关键词 左旋多巴 结肠 一氧化氮合酶 酪氨酸羟化酶 帕金森病 Levodopa colon nitric oxide synthase tyrosine hydroxylase Parkinson's disease
  • 相关文献

参考文献15

  • 1PFEIFFER RF. Gastrointestinal dysfunction in Parkinson's disease[J]. Parkinsonism and Related Disorders, 2011, 17: 10-15.
  • 2FAHN S, OAKES D, SHOULSON I, et al. Levodopa and the progression of Parkinzon's disease [J]. N Engl J Med, 2004, 351: 2498-2508.
  • 3LU CL, SHA.N DE, CHEN CY, et al. Impaired gastric myoelectrical activity in Patients with Parkinson's disease and effect of levodopa treatment[J]. Dig Dis Sci, 2004, 49: 744-749.
  • 4CJAUMETTE T, LEBOUVIER T, AUBERT P, et al. Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism [J]. Neurogastroenterol Motil, 2009, 21: 215-222.
  • 5ANDERSON G, NOORIAN A R, TAYLOR G, et al. Loss of enteric dopmninergie neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease[J]. Exp Neurol, 2007, 207: 4-12.
  • 6TIAN YM, CHEN X, LUO DZ, et al. Alteration of dopaminergic markers in gastrointeslinal tract of different rodent models of Parkinson's Disease[J]. Neuroscience, 2008, 153: 634-644.
  • 7WOLFGANG HJ. Gastrointestinal dysfunction in Parkinson's Disease[J]. Journal of the Neurological Sciences, 2010, 289: 69-73.
  • 8POEWE W. Non-motor symptoms in Parkinson's disease [J]. Eur J Neuroi, 2008, 15(Suppl 1): 14-20.
  • 9GREENE JG, NOORIAN AR, SRINVASAN S. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease [J]. Exp Neurol, 2009, 218: 154-161.
  • 10LEBOUVIER T, NEUNLIST M, BRULRY DES VARANNES S, et al. Colonic biopsies to assess the neuropathology of Parkinson's Disease and its relationship with symptoms [J]. Plos One, 2010, 5(9): e12728.

二级参考文献18

  • 1Jost W H. Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management [ J ]. Drugs Aging, 1997, 10:249-258.
  • 2Pfeiffer R F. Gastrointestinal dysfunction in Parkinson's disease[ J]. Lancet Neurol, 2003,2 : 107-116.
  • 3Banach T, Zurowski D, Gil K, et al. Peripheral mechanisms of intestinal dysmotility in rats with salsolinol induced experimental Parkinson' s disease [ J ]. J Physiol Pharmacol, 2006,57:291-300.
  • 4Banach T, Zurowski D, Kania D, et al. Myoelectrical activity of small intestine in rats with experimental Parkinson ' s disease[ J]. Folia Med Cracov, 2005,46 : 119- 124.
  • 5Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons[ J ]. Eur J Pharmacol, 1968,5: 107-110.
  • 6Cenci M A, Kalen P, Mandel R J, et al. Dopaminergic transplants normalize amphetamine-and apomorphine-induced Fos expression in the 6-hydroxydopamine-lesioned striatum[ J]. Neuroscienee, 1992,46:943-957.
  • 7Lubowski D Z, Swash M, Henry M M. Neural mechanisms in disorders of defaecation [ J ]. Baillieres Clin Gastroenterol, 1988,2-201-223.
  • 8Jost W H, Schimrigk K. Constipation in Parkinson's disease [ J]. Klin Wochenschr, 1991,69:906-909.
  • 9Mathers S E, Kempster P A, Swash M, et al. Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: a dystonic phenomenon[J].J Neurol Neurosurg Psychiatry, 1988,51 : 1503- 1507.
  • 10Edwards L L, Pfeiffer R F, Quigley E M, et al. Gastrointestinal symptoms in Parkinson's disease [J].Mov Disord, 1991,6 : 151-156.

共引文献3

同被引文献68

  • 1陆建明,周厚广.帕金森病大鼠模型的行为学及神经元形态学评价(英文)[J].中国临床康复,2004,8(16):3180-3182. 被引量:5
  • 2范国华,陈生弟,戚辰,赵静,陆国强.帕金森病小鼠模型脑黑质区热休克蛋白的表达[J].中国现代神经疾病杂志,2005,5(1):28-34. 被引量:1
  • 3邹志浩,张世忠,姜晓丹,徐如祥,肖炳祥,唐劭年,郭续文,徐强,杜谋选,蔡颖谦.6-羟基多巴定向注射建立帕金森病大鼠模型的实验研究[J].中华神经医学杂志,2006,5(3):244-247. 被引量:19
  • 4范国华,陈生弟,曹文俊,赵静.帕金森病模型中热休克蛋白mRNA的表达[J].中华神经科杂志,2006,39(4):266-268. 被引量:2
  • 5ALVAREZ-ERVITI L, SEOW Y, SCHAPIRA AHV, et al. Influ- ence of microRNA deregulation on chaperone-mediated autophagy and c:-synuclein pathology in Parkinson's disease[J]. Cell Death & Disease, 2013, 4(3): e545.
  • 6SULZER D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease[J]. Trends in Neurosciences, 2007, 30(5): 244- 250.
  • 7MAO Z, BONNI A, XIA F, et al. Neuronal activity-dependent cell survival mediated by transcription factor MEF2[J]. Science, 1999, 286(5440): 785-790.
  • 8PRIGIONE A, BEGNI B, GALBUSSERA A, et al. Oxidative stress in peripheral blood mononuclear ceils from patients with Parkinson's disease: negative correlation with levodopa dosage[J]. Neurobiology of Disease, 2006, 23(1): 36-43.
  • 9MOORE DJ, WEST AB, DIKEMAN DA, et al. Parkin mediates the degradation - independent ubiquitination of Hsp70[J]. Journal of Neurochemistry, 2008, 105(5): 1806-1819.
  • 10WU G, WANG X, FENG X, et al. Altered expression of au- tophagic genes in the peripheral leukocytes of patients with spo- radic Parkinson's disease[J]. Brain Research, 2011, 1394:105-111.

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部